This article is more than 5 years old. Information may no longer be current.
ABO blood type increased risk for VTE
Click Here to Manage Email Alerts
Those with ABO blood type are at a 20% greater risk for venous thromboembolism than the general population, according to results of a study conducted in Denmark.
Researchers aimed to determine whether ABO blood type alone and with mutations in Factor V Leiden R506Q and prothrombin G20210A carries an increased risk for VTE and myocardial infarction at the population level.
The researchers pulled data from two Danish studies that followed participants between 1977 and 2010.
Genotype data for 66,001 white participants for ABO blood type, Factor V Leiden R506Q and prothrombin G20210A were obtained.
VTE and MI served as the primary endpoints.
Multivariate analysis results indicated an HR of 1.4 (95% CI, 1.3-1.5) for VTE in those with a non-O blood type compared with O blood type.
Compared with noncarriers of the mutation, heterozygous Factor V Leiden R506Q mutation yielded an adjusted HR of 2.2 (95% CI 2.0-2.5), and homozygous carriers had an HR of 7 (95% CI, 4.8-10).
The HR for prothrombin G20210A was 1.5 (95% CI 1.2-1.9) in the heterozygous group and 11 (95% CI, 2.8-44) for the homozygous group compared with the non-mutation group.
A stepwise increase in VTE risk was observed when the three factors — ABO blood type and Factor V Leiden R506Q or prothrombin G20210A genotype — were combined (trend, P<.001).
ABO blood type was associated with a population attributable risk for VTE of 20%. A 10% population attributable risk for this event was observed in the Factor V Leiden R506Q group and 1% risk was observed for prothrombin G20210A.
“Blood type was the most important risk factor for venous thromboembolism in the general population,” the researchers wrote. “This suggests that ABO blood type should be considered for inclusion in genetic screening for thrombophilia.”
Multivariate results indicated that genotype did not affect MI risk.
Click Here to Manage Email Alerts